Contineum Therapeutics Inc.
Organization details
- Legal name
- Contineum Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CTNM
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001855175
- EIN
- 27-1467257
Board of directors
-
Carmine N. Stengone · Director · CEO and PresidentSince 2024
-
Evert B. Schimmelpennink · DirectorSince 2024
-
Gines Diego Miralles · DirectorSince 2025
-
Lori Lyons-Williams · DirectorSince 2024
-
Olivia C. Ware · DirectorSince 2024
-
Sarah Boyce · DirectorSince 2024
-
Todd R. Brady · DirectorSince 2024
-
Troy A. Ignelzi · DirectorSince 2024
Chief executives
Director election results
Annual meeting of June 26, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
94.0%
-
99.4%
Board connections
5 of this board's directors also sit on 7 other boards. 7 are in the same sector.
-
Artiva Biotherapeutics Inc. Same sectorvia Gines Diego Miralles
-
Atrium Therapeutics Inc. Same sectorvia Sarah Boyce
-
Harmony Biosciences Holdings Inc. Same sectorvia Troy A. Ignelzi
-
Kiora Pharmaceuticals Inc. Same sectorvia Carmine N. Stengone
-
LENZ Therapeutics Inc. Same sectorvia Evert B. Schimmelpennink
-
OmniAb Inc. Same sectorvia Sarah Boyce
-
iBio Inc. Same sectorvia Evert B. Schimmelpennink
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $1,858,437
- 31 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 8, 2026 | Carmine N. Stengone Director, Officer (CEO and President) | Option exercise | +2,500 | $1.01 | $2,525 |
| Sep 8, 2026 | Carmine N. Stengone Director, Officer (CEO and President) | Open-market sale | −2,500 | $16.46 | $41,150 |
| Aug 3, 2026 | Carmine N. Stengone Director, Officer (CEO and President) | Option exercise | +2,500 | $1.01 | $2,525 |
| Aug 3, 2026 | Carmine N. Stengone Director, Officer (CEO and President) | Open-market sale | −2,500 | $16.01 | $40,025 |
| Jul 9, 2026 | Lorrain Daniel S. Officer (Chief Scientific Officer) | Option exercise | +25 | $1.01 | $25 |
| Jul 9, 2026 | Lorrain Daniel S. Officer (Chief Scientific Officer) | Open-market sale | −25 | $16.00 | $400 |
| Jul 8, 2026 | Carmine N. Stengone Director, Officer (CEO and President) | Option exercise | +2,500 | $1.01 | $2,525 |
| Jul 8, 2026 | Lorrain Daniel S. Officer (Chief Scientific Officer) | Option exercise | +1,015 | $1.01 | $1,025 |
| Jul 8, 2026 | Carmine N. Stengone Director, Officer (CEO and President) | Open-market sale | −2,500 | $16.00 | $40,000 |
| Jul 8, 2026 | Lorrain Daniel S. Officer (Chief Scientific Officer) | Open-market sale | −1,015 | $16.00 | $16,240 |
| Jul 1, 2026 | Lorrain Daniel S. Officer (Chief Scientific Officer) | Option exercise | +4,183 | $1.01 | $4,225 |
| Jul 1, 2026 | Lorrain Daniel S. Officer (Chief Scientific Officer) | Open-market sale | −5,852 | $15.67 | $91,701 |
| Jul 1, 2026 | Lorrain Daniel S. Officer (Chief Scientific Officer) | Open-market sale | −2,501 | $16.24 | $40,616 |
| Jun 30, 2026 | Carmine N. Stengone Director, Officer (CEO and President) | Option exercise | +7,500 | $1.01 | $7,575 |
| Jun 30, 2026 | Watkins Tim Officer (CMO & Head of Development) | Option exercise | +10,833 | $4.50 | $48,749 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Contineum Therapeutics Inc.
Who is the CEO of Contineum Therapeutics Inc.?
Carmine N. Stengone has been Contineum Therapeutics Inc.'s CEO and President since April 2024.
How many directors are on Contineum Therapeutics Inc.'s board?
Contineum Therapeutics Inc.'s board has 8 directors: Carmine N. Stengone, Evert B. Schimmelpennink, Gines Diego Miralles, Lori Lyons-Williams, Olivia C. Ware, Sarah Boyce, Todd R. Brady and Troy A. Ignelzi.
Are Contineum Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Contineum Therapeutics Inc. insiders made no open-market purchases and sold $1.9 million of shares in 31 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="contineum-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.